579 results about "Glycation" patented technology

A method of determining glycated hemoglobin is provided, by which a ratio of the glycated hemoglobin in a sample can be determined accurately and easily. The ratio of glycated hemoglobin can be determined by degrading a glycated hemoglobin in a whole blood sample selectively with a protease to give a glycated hemoglobin degradation product; causing a redox reaction between a glycation site of the glycated hemoglobin degradation product and a fructosyl amino acid oxidoreductase; and determining this redox reaction. Further, as shown in FIG. 1, in a whole blood sample, there is a correlation between the ratio of the glycated hemoglobin determined by this method and an HbA1c concentration. Thus, without determining the glycated α-amino group as a characteristic structure of HbA1c, an amount of HbA1c can be determined accurately and easily from the determined ratio of the glycated hemoglobin.

Embodiments of the present invention provide an apparatus suitable for determining properties of in vivo tissue from spectral information collected from the tissue. An illumination system provides light at a plurality of broadband ranges, which are communicated to an optical probe. The optical probe receives light from the illumination system and transmits it to in vivo tissue, and receives light diffusely reflected in response to the broadband light, emitted from the in vivo tissue by fluorescence thereof in response to the broadband light, or a combination thereof. The optical probe communicates the light to a spectrograph which produces a signal representative of the spectral properties of the light. An analysis system determines a property of the in vivo tissue from the spectral properties. A calibration device mounts such that it is periodically in optical communication with the optical probe.

Disclosed herein are dietary formulations and methods to mimic the physiological, biochemical and gene expression effects of calorie restriction without altering dietary intake. The formulations include combinations of nutrients that have various intended functions in the body, falling into three or more of the following activities; (1) antioxidant activity; (2) inhibition of glycation damage; (3) reduction of body weight and fat; and (4) promotion of high insulin sensitivity and low blood insulin / glucose; and (5) anti-inflammatory activity.

The invention discloses a genetic engineering cell line for producing an unfucosylated protein and an establishment method thereof. The invention utilizes the CRISPR / Cas9 technique to knock out the Slc35cl gene and / or the Fut8 gene in host cells, and thereby the Slc35cl gene-silencing and / or Fut8 gene-silencing stable genetic engineering cell line is obtained. By utilizing the genetic engineering cell line disclosed by the invention, the protein from which fucosylation is completely removed can be produced, moreover, the protein is still stable after 30 generations of passage, and thereby the two major problems of incomplete fucosylation removal and unstable passage in the prior art are solved. An unfucosylated antibody produced by the method disclosed by the invention shows enhanced ADCC (antibody dependent cell-mediated cytotoxicity) activity, and thereby the clinical therapeutic effect of the antibody is enhanced.

A method of determining a measure of a tissue state (e.g., glycation end-product or disease state) in an individual. A portion of the tissue of the individual is illuminated with excitation light, then light emitted by the tissue due to fluorescence of a chemical with the tissue responsive to the excitation light is detected. The detected light can be combined with a model relating fluorescence with a measure of tissue state to determine a tissue state. The invention can comprise measuring the fluorescence lifetime in either time-domain or frequency domain modes. The invention can also comprise a variety of models relating fluorescence to a measure of tissue state, including a variety of methods for generating such models. For example, multivariate models can be developed that relate lifetime trends of one or more constituents to increasing propensity to diabetes and pre-diabetes. Other biologic information can be used in combination with the fluorescence properties to aid in the determination of a measure of tissue state. The invention also comprises apparatuses suitable for carrying out the method, including appropriate light sources, detectors, and models (for example, implemented on computers) used to relate detected fluorescence and a measure of tissue state.

A home test for measuring glycated albumin levels in saliva. The saliva sample is collected at home using a standardized saliva collection kit and mailed to a testing laboratory that performs the test and reports the result directly back to the customer via the internet. The home test can be used to monitor glucose control in diabetics and in healthy individuals. It may also be used as a diagnostic aid in identifying individuals with diabetes, or who are at risk of developing diabetes.

A non-enzymatic electrochemical method of simultaneous measurement of hemoglobin (Hb) and percentage of glycated hemoglobin (% HbA1c) in a blood sample is disclosed. The method includes determining the total amount of hemoglobin in a sample by electrochemically measuring the voltammetric current due to iron (II) and iron (III) redox portions in hemoglobin and determining the percentage of glycated hemoglobin (HbA1c) by potentiometry. Also disclosed is a novel screen-printed electrode (SPE) strip modified for potentiometric measurement of HbA1c.

The present invention relates to the optical measurement of blood analytes, such as glycated hemoglobin (HbA1c) and serum albumin as a functional metric of mean blood glucose in the diagnosis of diabetic patients. Non-enhanced Raman spectroscopy is employed as the analytical method for quantitative detection of blood analytes. Using processing techniques, non-enzymatic glycosylation (glycation) of the analytes results in measurable and highly reproducible changes in the acquired spectral data, which enable the accurate measurements and classification of glycated and unglycated analytes.

The invention discloses a high-yield method for co-producing the resistant dextrin, the beta-cyclodextrin and the F42 HFCS. According to the process, corn starch serves as a raw material, digestible dextrin is converted into the beta-cyclodextrin through burning, liquefaction and addition of cyclodextrin glucoxyltransferase, and composite insoluble substances are obtained through toluene composition and filtered, toluene is recycled and the beta-cyclodextrin is obtained; the surplus solution is subjected to composite saccharifying enzyme saccharification, chromatographic separation and refining, and resistant dextrin and corn syrup are obtained; and the corn syrup is subjected to isomerization and fining, and the F42 HFCS is obtained. According to the method, the high-purity resistant dextrin can be produced, the application field of the resistant dextrin is expanded, the surplus digestible mother solution is effectively used to produce the beta-cyclodextrin and the F42 HFCS, the production cost is greatly reduced, and the material usage rate and the yield are improved apparently.

A method of determining Hb is provided, by which an amount of Hb can be determined easily and accurately without fear of damage to the environment. Hemoglobin in a sample is denatured with a tetrazolium compound to give denatured hemoglobin, and an amount of an optical change in the sample is measured at an absorption wavelength specific to the denatured hemoglobin. Using the amount of the optical change thus measured, an amount of the hemoglobin in the sample can be determined. The amount of the optical change preferably is measured at a wavelength in a range from 520 to 670 nm. According to this method, an amount of Hb can be determined with high accuracy as shown in FIG. 1.

A rapid immunochromatographic assay system is provided for measuring the amount of glycated albumin in a blood sample relative to the total level of albumin in the sample. The assay system is comprised of a disposable cassette that contains the test strips and testing reagents, and a measurement device that automatically reads, calculates and displays the test results over a period of time. The test cassette contains two test strips that are used to measure glycated albumin and total albumin respectively. The strips are contiguous beneath the single sample application well so that the same sample is tested simultaneously by both test strips. Part of the sample will migrate thru the glycated albumin test strip where it will react with the glycated albumin test reagents to yield a glycated albumin result, while part of the sample will migrate thru the total albumin test strip where it will react with the total albumin test reagents to yield a total albumin result. The test cassette is placed within a measuring device such as a reflectance spectrometer or fluorometer, that reads, calculates and expresses the result as the percentage of glycated albumin relative to total albumin in the sample. The results of successive testing that are performed over a period of time are stored in the instrument's memory and displayed in a numerical or graphical format so that the individual's glycated albumin levels can be monitored over time.

The present invention relates to the use of an active substance that promotes the inhibition of the formation of AGEs, for preparing a composition to prevent and / or combat the reduction in elastic and plastic properties of tissues, and in particular of the skin, for inhibiting the formation of AGEs, or for preventing and / or combating glycation of proteins in the skin. The invention also relates to a method of screening such active substances.

A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's; or Fabry's disease. Methods of decreasing plasma TNF-α, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentrations in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.

PCT No. PCT / DK95 / 00511 Sec. 371 Date Aug. 14, 1997 Sec. 102(e) Date Aug. 14, 1997 PCT Filed Dec. 20, 1995 PCT Pub. No. WO96 / 19582 PCT Pub. Date Jun. 27, 1996A method of producing a milk clotting enzyme including the steps of (a) fermenting a strain of Rhizomucor miehei or Aspergillus oryzae to form a fermentation product having a glycoslated Rhizomucor miehei aspartic protease and other proteins, and (b) subjecting a quantity of the fermentation product to a deglycosylating treatment to form a coagulant preparation having an at least partly deglycoslated aspartic protease and the other proteins. The at least partly deglycosylated protease has a milk clotting activity that is at least 10% higher than a milk clotting activity of the glycosylated aspartic protease.

The invention provides a recombinant saccharomyces cerevisiae strain for continuously and efficiently secreting beta-glucosidase, which is named Saccharomyces cerevisiae 102SB, and preserved with a Preservation No. of CGMCC No. 7450 in the China General Microbiological Culture Collection Center on April 11, 2013. The recombinant saccharomyces cerevisiae disclosed by the invention can continuously and efficiently secrete beta-glucosidase in a complex non-selective medium, and the extracellular enzyme activity can reach 1005.3 U / g (dry weight). By using a characteristic that the maximum specific growth rate of cellobiose is consistent with that of glucose, the strain reaches 0.29 h<-1> under the condition of limited oxygen. In SSF taking a cellulose material as a substrate, the yield of ethanol taking microcrystalline cellulose as a substrate is increased by 110%, and the yield of ethanol taking acid-hydrolyzed corncobs as a substrate is increased by 89%. The recombinant saccharomyces cerevisiae strain disclosed by the invention is of great importance in reducing the production cost of simultaneous saccharification and fermentation in the process of cellulosic ethanol production, and simplifying the production process.

The invention discloses a preparation method of special starch syrup for QQ sugar, which comprises the following steps: (1) pulping, and liquefying; (2) performing high-temperature filtration; (3) performing low-temperature filtration; (4) saccharifying; (5) decoloring; (6) performing ion exchange desalination; and (7) concentrating. The special starch syrup for QQ sugar, prepared according to the method, comprises the following sugar components: 0.8-1.2% of glucose, 44-48% of maltobiose, 17-19% of maltotriose and 38-42% of maltotetrose. The invention has the following advantages: (1) fine control is performed on the liquefied liquid glucose components through a special injection and liquefying process, thus obtaining low liquefaction liquid having high DE value; (2) high-temperature deslagging filtration and low-temperature protein flocculation are performed, thereby being more beneficial to impurity removal; (3) a mixed enzyme preparation is added in the saccharifying process, thus regulating and controlling the content of the sugar contents more effectively; and (4) the finished product is high in polysaccharide content, and the content of the sugar components presents a discontinuous ascending ratio, thus having a special physiological function.